Tioriva Bexicap Capsule
Tioriva® Bexicap is indicated for the long-term treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Adult over 18 years: The recommended dose of Tioriva® Bexicap capsule is 18 mcg (1 capsule) once-daily, with the device. The contents of the Tioriva® Bexicap capsules are only for oral inhalation and should only be used with the Bexihaler device.
Tioriva® Bexicap (Dry Powder Inhaler) capsule contains Tiotropium Bromide Monohydrate BP as the active ingredient which is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. Tioriva® is indicated as maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Related products
